Singapore, May 7 -- Sciwind Biosciences Co., a clinical stage biopharmaceutical company focused on developing treatments for metabolic disease, and HK inno.N Corporation, a South Korean commercial stage pharmaceutical company, have announced a licensing and partnership agreement for the development and commercialisation of ecnoglutide injection (XW003), a novel GLP-1 analog for the treatment of type 2 diabetes, obesity and metabolic dysfunction-associated steatohepatitis (MASH), in South Korea.

Under the terms of the agreement, Sciwind Biosciences will receive an upfront payment and will be eligible to receive additional development, regulatory, and commercial milestones of up to $56 million, as well as up to double-digit royalties from ...